The End of the Injection? Orbis Taps Veteran CEO for Oral Biologics Race

COPENHAGEN – October 27, 2026

For decades, the structural integrity of advanced medical care has been tethered to a remarkably fragile supply chain: the cold-storage vial and the hypodermic needle. Biologics—the complex, large-molecule therapies that have revolutionized the treatment of everything from rheumatoid arthritis to oncology—have historically demanded clinical infrastructure for intravenous or subcutaneous delivery. This physical requirement inherently limits patient access, strains healthcare systems, and delineates a stark boundary between those who can easily navigate the medical apparatus and those who cannot.

Today, that boundary is facing a formidable challenge. Orbis Medicines, a biotechnology firm operating at the vanguard of artificial intelligence and synthetic chemistry, has announced a pivotal leadership transition designed to shepherd its portfolio of oral macrocycles from computational concept to clinical reality. The company has appointed biopharmaceutical veteran Joanne Smith-Farrell, Ph.D., as Chief Executive Officer, signaling a definitive shift from an early-stage platform builder to a clinical-stage contender. She succeeds co-founder Morten Graugaard, who transitions to Chief Business Officer to manage a rapidly expanding web of strategic alliances.

From Computational Promise to Clinical Execution

The appointment of Dr. Smith-Farrell is a calculated maneuver in a high-stakes industry. Transitioning a biotechnology company from a research-focused platform into a clinical-stage pipeline requires a distinct operational architecture. During her tenure as CEO of Be Biopharma, Smith-Farrell orchestrated exactly this kind of metamorphosis, steering the organization through more than $350 million in cumulative financing and driving its lead hemophilia B program into human trials.

Her earlier tenure as Chief Operating Officer and Head of the Oncology Business Unit at bluebird bio offers perhaps the most forensic look at her operational playbook. There, she scaled a nascent oncology effort into a robust commercial enterprise, culminating in the approval of Abecma, a first-in-class CAR-T therapy for multiple myeloma. Cell therapies represent some of the most logistically complex treatments in modern medicine. Now, at Orbis, Smith-Farrell is tasked with the inverse challenge: radically simplifying drug delivery by replacing the clinic visit with a daily pill.

“Orbis is entering an ambitious new phase of growth at a time when the industry is increasingly seeking oral alternatives to injectable biologics to bring important medicines to more patients,” said Dr. Smith-Farrell in the company’s announcement. “Morten and the team, backed by leading life sciences investors, have built a strong company to discover oral macrocycles that work like biologics. I am honored to lead this team as we develop a pipeline of medicines that matter to patients.”

Cracking the Biologic Pill

To understand the magnitude of Orbis’s ambition, one must examine the fundamental physics of pharmacology. Traditional biologics are massive, fragile proteins. When ingested, the human gastrointestinal tract treats them as food, deploying acids and enzymes to dismantle them long before they can cross the intestinal wall into the bloodstream. Historically, the oral bioavailability of peptide drugs has hovered around a dismal one to two percent.

Orbis is circumventing this biological fortress through its proprietary nGen platform, which designs fully synthetic macrocycles termed nCycles. These molecules occupy a structural sweet spot—typically between 500 and 1000 daltons. They are significantly smaller than legacy macrocycles but large enough to bind to the complex protein targets previously reserved for bulky injectable biologics.

The scientific foundation of this approach, pioneered by Orbis founders Professor Christian Heinis and Dr. Sevan Habeshian at EPFL, has been rigorously validated in peer-reviewed journals such as Nature Communications and Nature Chemical Biology. In laboratory settings, these synthetic macrocycles have achieved an unprecedented 18 percent oral bioavailability, a quantum leap over historical baselines.

This breakthrough is not merely a triumph of traditional chemistry; it is a testament to the integration of generative AI. The nGen platform operates as a closed-loop system, training machine learning models on vast, proprietary datasets of experimental macrocycles. By leveraging high-throughput synthesis and advanced computational power—including recent integrations with Denmark’s Gefion AI supercomputer—Orbis can rapidly iterate molecular designs, optimizing for both target affinity and membrane permeability.

“Oral medicines with the potency of biologics could broaden patient access well beyond what injectables allow today — a major addition to the industry’s medicine cabinet,” noted Mikael Dolsten, M.D., Ph.D., Chairperson of the Board at Orbis.

The Billion-Dollar Blueprint and Market Dynamics

The transition of Morten Graugaard to Chief Business Officer highlights the dual-track strategy that Orbis is deploying to finance its ambitions. While Dr. Smith-Farrell focuses on advancing the company’s wholly owned immunology and inflammation programs, Graugaard will manage external partnerships, building upon the massive collaboration he helped architect with Novo Nordisk.

Valued at up to $1.4 billion in upfront, development, and commercial milestones, the Novo Nordisk alliance is focused on discovering next-generation oral macrocycles for cardiometabolic diseases. This partnership not only provides Orbis with substantial non-dilutive capital but also validates the nGen platform in the eyes of the broader pharmaceutical industry.

“It has been a privilege to build Orbis from a concept into a company with a platform validated through our Novo Nordisk partnership,” said Mr. Graugaard. “I am delighted to welcome Joanne, and I look forward to building the partnerships that will be a key driver of our growth alongside our own programs.”

Orbis is not alone in recognizing the immense potential of this space. The global oral protein and peptide market is projected to surge toward $47 billion by the middle of the next decade. Competitors are aggressively staking their claims. Merck & Co. is advancing its investigational oral PCSK9 inhibitor, enlicitide, through Phase 3 trials, aiming to replicate the cholesterol-lowering effects of injectable biologics. Meanwhile, biotech firms like Unnatural Products have secured multi-billion-dollar licensing agreements with giants like Novartis and argenx to develop their own orally delivered macrocyclic peptides.

In this highly competitive landscape, Orbis’s EUR 116 million venture war chest—bolstered by a EUR 90 million Series A led by NEA and supported by Novo Holdings, Forbion, and Lilly Ventures—provides the necessary capital to scale its clinical operations and defend its intellectual property.

The Equity of Access in a Post-Injection World

From a structural perspective, the race to develop oral biologics is about much more than pharmaceutical market share; it is fundamentally about social equity and public health infrastructure. The reliance on injectable biologics has inadvertently created a tiered healthcare system. Patients in rural areas, developing nations, or underfunded municipalities often face insurmountable barriers to accessing therapies that require strict cold-chain logistics and specialized clinical administration.

By engineering therapies that offer biologic-like potency in a shelf-stable, orally bioavailable format, companies like Orbis are doing more than innovating chemical structures; they are dismantling the logistical barriers that have historically dictated who receives state-of-the-art care. A daily pill bypasses the clinic, bypasses the cold chain, and places the power of advanced medicine directly into the hands of the citizen.

As Orbis Medicines enters this critical new phase under the leadership of Dr. Smith-Farrell, the broader implications of its technology will be closely monitored. The intersection of generative artificial intelligence and synthetic chemistry has the potential to rewrite the social contract of modern medicine, proving that the most profound disruptions often come in the smallest, most accessible packages.